RadNet Inc

RadNet reported second-quarter 2026 adjusted earnings of 29 cents per share, down 14.7% year over year but beating the Zacks Consensus Estimate of 18 cents by 61.1%. Revenue rose 25% to $622.7 million, topping the consensus mark by 1.4%, driven by stronger advanced imaging volumes, recent acquisitions, and Digital Health expansion. The company raised its 2026 Imaging Center revenue guidance to $2.37-$2.42 billion from the prior $2.355-$2.405 billion, and increased adjusted EBITDA and free cash flow outlooks for that segment. Digital Health annual recurring revenues reached $105.5 million, up 97% year over year, and the company plans to deploy its newly FDA-cleared DeepHealth breast ultrasound AI solution across its network by year-end.

RadNet’s wholly owned subsidiary DeepHealth launched Reporting Pro for commercial deployment on June 10. The product integrates speech recognition, AI-generated findings, measurements, impressions, quality assurance, and structured reporting into a single radiology workflow. The launch aims to improve throughput, reporting speed, and quality control across RadNet’s network of outpatient diagnostic imaging centers. Analysts see about 30.6% average upside for RadNet shares, viewing the technology push as a way to make the outpatient imaging model more scalable.

DeepHealth, a wholly owned subsidiary of RadNet, has received FDA clearance for two new functionalities within its AI-powered Breast Suite. The clearances cover Breast Arterial Calcification Assessment, which automatically detects breast arterial calcifications on standard mammograms to identify potential cardiovascular disease risk, and Mammo Dx, which compares current and prior mammograms to track lesion changes and improve cancer detection. Both tools are now commercially available in the United States and will be deployed across RadNet imaging centers for real-world validation. The additions transform the Breast Suite into a fully integrated platform supporting cancer detection, cardiovascular risk assessment, breast density evaluation, and workflow optimization, currently used in over 10 million mammograms annually worldwide.